Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting

• Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). 
• As of October 31, 2021, at the final analysis, a significant improvement in PFS was detected in the toripalimab arm over the placebo arm, with a median PFS of 8.4 vs. 5.6 months. 
• The 1-year PFS rates for the toripalimab and placebo arms were 36.7% and 17.2%, respectively.
• Related: Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer.
• A prespecified interim analysis demonstrated a statistically significant improvement in overall survival for the toripalimab arm over the placebo arm (median OS not reached vs. 17.1 months).
• The addition of toripalimab to standard first-line chemotherapy in patients with advanced NSCLC showed a manageable safety profile with no new safety signals observed. 
• Price Action: CHRS shares are up 5.51% at $12.73 during the market session on the last check Tuesday.